StockSignal
Syndax Pharmaceuticals Inc.
SNDX · XNCM · Biotechnology · United States
Market Capitalization2.12B USD
Trailing P/E-7.33 USD
52-Week Change44.21 USD
Beta0.4560 USD
Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The primary mission of Syndax is to enhance and extend the lives of patients by significantly improving the efficacy of cancer therapies. Notably, the company is developing a pipeline of investigational drugs that aim to boost the immune system's ability to fight cancer and target the underlying genetic causes of cancer growth and persistence. Syndax Pharmaceuticals is particularly involved in researching epigenetic therapies and immuno-oncology, paving the way for new treatment paradigms. The company's contributions affect both the pharmaceutical industry and the wider healthcare sector by potentially offering new, effective therapeutic options for oncologists and their patients. As such, Syndax plays a vital role in the growing field of cancer therapeutics and continues to explore partnerships and collaborations to advance its groundbreaking research and development efforts.
Industry
Biotechnology
Healthcare sector · United States
Stories
Structural patterns identified in Syndax Pharmaceuticals Inc.
No stories identified yet.
Key Metrics
Market Capitalization
2.12BUSDTrailing P/E
-7.33USDRevenue (TTM)
172.35MUSDProfit Margin
-165.60%Beta
0.4560USD52-Week Change
44.21USDThis company does not currently pay dividends.
Valuation9
Market Capitalization
2.12BUSDEnterprise Value
2.06BUSDTrailing P/E
-7.33USDForward P/E
-152.32USDPEG Ratio
0.2521USDPrice to Sales (TTM)
12.33USDPrice to Book (MRQ)
32.60USDEnterprise to Revenue
11.93USDEnterprise to EBITDA
-7.52USDProfitability & Growth50
Gross Margin
96.06%Profit Margin
-165.60%Operating Margin
-91.59%Return on Assets (TTM)
-0.2725USDReturn on Equity (TTM)
-1.62USDRevenue (TTM)
172.35MUSDRevenue per Share (TTM)
1.99USDQuarterly Revenue Growth
7.95USDGross Profit (TTM)
-93.40MUSDEBITDA
-273.48MUSDNet Income (TTM)
-285.42MUSDQuarterly Earnings Growth (YoY)
7.95USDOperating Cash Flow (TTM)
-322.98MUSDLevered Free Cash Flow (TTM)
-210.05MUSDTrailing Annual Dividend Rate
0.00USDTrailing Annual Dividend Yield
0.00%Payout Ratio
0.00USDRevenue
172.35MCost of Goods Sold
6.97MGross Profit
165.38MOperating Income
-273.08MPre-tax Income
-285.42MNet Income
-285.42MEBIT
-251.64Mebitda-income
-251.63MResearch & Development
258.78MSelling, General & Administrative
179.68MNon-operating Interest Income
22.73MNon-operating Interest Expense
33.78MEPS (Basic)
-3.29EPS (Diluted)
-3.29Basic Shares Outstanding
86.63MSharesDiluted Shares Outstanding
86.63MSharesNet Income from Continuing Operations
-285.42MOperating Cash Flow
-343.52MFree Cash Flow
-323.17MCash & Cash Equivalents (End of Period)
135.03MInterest Paid
13.19MNet Income (CF Statement)
-285.42MDepreciation & Amortization
6.00KStock-based Compensation
47.50MOther Non-cash Items
1.34MChange in Accounts Receivable (CF)
-79.81MChange in Accounts Payable (CF)
4.95MChange in Other Assets/Liabilities
-32.09MCapital Expenditures
-187.00KPurchase of Investments
-195.81MSale of Investments
486.03MNet Investing Cash Flow
290.04MNet Financing Cash Flow
0.00Financial Strength31
Shares Outstanding
87.41MSharesFloat Shares
74.69MUSDShares Short
21.80MSharesShort Ratio
18.12USDShort % of Shares Outstanding
0.2783USD% Held by Insiders
0.0181USD% Held by Institutions
1.17USDTotal Cash (MRQ)
413.69MUSDTotal Cash per Share (MRQ)
4.69USDTotal Debt (MRQ)
345.43MUSDTotal Debt to Equity (MRQ)
534.48USDCurrent Ratio (MRQ)
4.40USDBook Value per Share (MRQ)
0.7390USDTotal Assets
529.71MTotal Current Assets
528.08MTotal Liabilities
465.08MTotal Non-current Assets
1.63MTotal Non-current Liabilities
344.96MTotal Current Liabilities
120.12MCash Equivalents
134.93MCash & Cash Equivalents
134.93MOther Short-term Investments
278.76MAccounts Receivable
38.00MInventory
32.75MAccounts Payable
16.58MShort-term Debt
472.00KOther Current Liabilities
10.53MLong-term Debt
344.96MCommon Stock (Book)
9.00KRetained Earnings
-1.51BTotal Shareholders' Equity
64.63MMarket & Technical10
52-Week Low
8.58USD52-Week High
25.44USD52-Week Change
44.21USDBeta
0.4560USD50-Day MA
21.50USD200-Day MA
16.47USDAvg 10-Day Volume
1.52MUSDAvg 30-Day Volume
1.37MUSDDiluted EPS (TTM)
-3.29USDOther Income / Expense
-1.28MCoordination
Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination